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TransdiagnosticAbroad array of transdiagnostic psychological treatments for depressive and anxiety disorders have been evaluated,
but existing reviews of this literature are restricted to face-to-face cognitive behavioural therapy (CBT) protocols.
The current meta-analysis focused on studies evaluating clinician-guided internet/computerised or face-to-face
manualised transdiagnostic treatments, to examine their effects on anxiety, depression and quality of life (QOL).
Results from 50 studies showed that transdiagnostic treatments are efﬁcacious, with large overall mean uncon-
trolled effects (pre- to post-treatment) for anxiety and depression (gs = .85 and .91 respectively), and medium
for QOL (g=.69). Uncontrolled effect sizeswere stable at follow-up. Results from24RCTs thatmet inclusion criteria
showed that transdiagnostic treatments outperformed control conditions on all outcomemeasures (controlled ESs:
gs= .65, .80, and .46 for anxiety, depression andQOL respectively),with the smallest differences found compared to
treatment-as-usual (TAU) control conditions. RCT quality was generally poor, and heterogeneity was high. Exami-
nation of the high heterogeneity revealed that CBT protocolsweremore effective thanmindfulness/acceptance pro-
tocols for anxiety (uncontrolled ESs: gs = .88 and .61 respectively), but not depression. Treatment delivery format
inﬂuenced outcomes for anxiety (uncontrolled ESs: group: g= .70, individual: g= .97, computer/internet: g= .96)
and depression (uncontrolled ESs: group: g= .89, individual: g= .86, computer/internet: g= .96). Preliminary
evidence from 4 comparisons with disorder-speciﬁc treatments suggests that transdiagnostic treatments are as ef-
fective for reducing anxiety, andmay be superior for reducing depression. These ﬁndings show that transdiagnostic
psychological treatments are efﬁcacious, but higher quality research studies are needed to explore the sources of
heterogeneity amongst treatment effects.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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Depressive and anxiety disorders (collectively referred to as emotional
disorders) represent one of the largest causes of disability worldwide,
with estimated lifetimeprevalence rates of up to 29% for anxiety disorders
and 19% for depressive disorders (Kessler et al., 2005). The economic bur-
den is enormous, with depression and anxiety accounting for a third to
onehalf of theglobal cost ofmental illness, currently estimatedat $2.5 tril-
lion (2010), and projected to increase to over $6 trillion by 2030 (WHO
Global Burden of Disease: 2004 update,WHO, 2008). Depressive and anx-
iety disorders typically develop in late adolescence/early adulthood, and
are chronic and relapsing if they remain untreated and even after acute
treatment (Judd, 1997). The burden of these disorders is difﬁcult to over-
state: they impair the quality of life of sufferers and their loved ones, re-
duce workforce participation, contribute to marked occupational
impairment and lost productivity (Birnbaum et al., 2010), and increase
risk for the development and morbidity associated with chronic physical
conditions (e.g., cardiovascular disease) (Katon, 2011).
Until relatively recently, the disorder-speciﬁc approach has domi-
nated the way in which depressive and anxiety disorders have been
conceptualised and researched, and has shaped the way treatmentshave been developed and evaluated. While this approach to treatment
has demonstrable efﬁcacy (Hofmann & Smits, 2008), there are also sig-
niﬁcant drawbacks. First, there is substantial discrepancy between the
disorder-speciﬁc treatment approach with our current understanding
of depressive and anxiety disorders. There is strong evidence indicating
that similar aetiological andmaintenance processes underlie depressive
and anxious psychopathology. For instance, anxiety and depressive dis-
orders share many similar genetic, familial, and environmental risk fac-
tors (Kendler, 1996; Kessler et al., 2005), with structural modelling
studies showing that a broad internalising liability or a common dis-
tress/negative affectivity component underlies anxiety and depressive
disorders (Andrews et al., 2009; Watson, 2005). These disorders also
share similar cognitive-affective, interpersonal, and behavioural main-
taining factors, with the similarities superseding any minor differences
between disorders (Harvey, Watkins, Mansell, & Shafran, 2004).
Second, disorder-speciﬁc interventions pay relatively limited attention
to comorbidity, despite evidence of high comorbidity rates up to 40–
80% in both clinical and epidemiological studies (Brown, Campbell,
Lehman, Grisham, &Mancill, 2001; Kessler et al., 2005). High comorbid-
ity poses a signiﬁcant problem for both conceptualisation and treatment
decisions: how should the treating practitioner provide optimal
Abbreviations
ACT acceptance and commitment therapy
AM+ VR anxiety management and virtual reality exposure
therapy
BA behavioural activation
CBT cognitive behaviour therapy
CCBT computerised cognitive behaviour therapy
GCBT group cognitive behaviour therapy
CG-ERP clinician guided exposure and response prevention
EBT evidence-based treatment
E-COM enhanced community treatment
F-SET false safety behaviour elimination therapy
GMBCT group mindfulness based cognitive therapy
GMBSR group mindfulness based stress reduction
GMBSM group mindfulness based stress management
iCBT internet-delivered cognitive behavioural therapy
iCBT (CO) internet cognitive behavioural therapy with coach
guidance
iCBT (CL) internet cognitive behavioural therapy with clinician
guidance
i-AFPP internet affect focused psychodynamic psychotherapy
IPT interpersonal psychotherapy
QOL quality of life
RT relaxation training
SC supportive counselling
SG-ERP self-guided exposure and response prevention
STPP short-term psychodynamic psychotherapy
T-CBT telephone-delivered cognitive behaviour therapy
TD transdiagnostic
TAU treatment-as-usual
WLC waiting list control
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majority of evidence-based treatments (EBTs) are tailored to speciﬁc
diagnoses?
Third, despite the clinical utility of diagnostic categories, there
are also some limitations to the reliability and validity of the diag-
nostic classiﬁcations that disorder-speciﬁc treatments have been
based on: there is considerable heterogeneity within diagnostic cat-
egories, poor discrimination between supposedly distinct emotional
disorders, and high rates of not otherwise speciﬁed diagnoses
(e.g., see Brown, Di Nardo, Lehman, & Campbell, 2001). In addition,
the ever-growing numbers of treatment manuals for different disor-
ders (and multiple manuals for the same disorder) represent a sig-
niﬁcant barrier to implementation, dissemination and training, and
EBT manuals often share many common elements (e.g., cognitive
restructuring) leading to signiﬁcant redundancy across treatment
protocols (Chorpita & Daleiden, 2009).
Driven by these concerns, there has been growing consensus amongst
international experts in the ﬁeld that a novel approach is needed in the
way we classify, formulate, treat, and prevent depression and anxiety
disorders (Barlow, Allen, & Choate, 2004). The move away from the
single-diagnosis approach towards a transdiagnostic conceptualisation
and treatment of depressive and anxiety disorders represents a signiﬁcant
paradigm shift (Craske, 2012), mirroring a similar shift in EBTs for eating
disorders (Fairburn, Cooper, & Shafran, 2003). The transdiagnostic
approach focuses on identifying the common and core maladaptive tem-
peramental, psychological, cognitive, emotional, interpersonal andbehav-
ioural processes that underpin a broad array of diagnostic presentations
(Harvey et al., 2004) and targeting these factors in treatment (Barlow
et al., 2004). ‘Transdiagnostic or ‘uniﬁed’ treatments apply the same un-
derlying treatment principals across mental disorders, without tailoringthe protocol to speciﬁc diagnoses’ (p21, McEvoy, Nathan, & Norton,
2009), and as such operate outside the traditional diagnostic boundaries
of DSM (American Psychiatric Association, 2013) or ICD (World Health
Organization, 1992). The transdiagnostic approach is also compatible
with the Research Domain Criteria (RDoC), put forth by the U.S. National
Institute forMentalHealth as an alternative toDSMor ICD, that focuses on
the underlying mechanisms (e.g., cognition, negative affect, arousal) that
cut across multiple disorders (see Cuthbert, 2014).
Transdiagnostic psychological treatments have been hailed as a prom-
ising new approach to overcome some of the pitfalls of disorder-speciﬁc
treatments (see Clark & Taylor, 2009; Craske, 2012 for a discussion of
the promise and pitfalls of the transdiagnostic approach). In theory,
transdiagnostic treatments should enable the treating practitioner to con-
ceptualise the common maintaining processes across presenting issues,
and deliver evidence-based treatment strategies within the one protocol,
increasing the efﬁciency and efﬁcacy of treatment, reducing the need for
multiple manuals, and increasing the ease of implementation (Chorpita,
Taylor, Francis, Mofﬁtt, & Austin, 2004). At present however, it is unclear
whether transdiagnostic treatments meet these high expectations. It re-
mains uncertain how efﬁcacious transdiagnostic treatments are in reduc-
ing anxiety and depression symptoms, and in improving quality of life. In
addition, although one of the supposed strengths of transdiagnostic treat-
ment approach is that it reduces the need for multiple treatment proto-
cols, an increasing number of transdiagnostic treatments are being
developed and evaluated around the world. These protocols differ with
respect to the diagnostic combinations and symptom proﬁles they are
designed to target (e.g., multiple anxiety disorders or anxiety and depres-
sion), the type of treatment techniques they use (e.g., cognitive behav-
ioural therapy [CBT] versus mindfulness-based treatments), and their
delivery format (e.g., group-based versus internet-delivered treatments),
but it is unknownwhether these differences affect outcomes. In addition,
many of the existing evaluations have been conducted with small sam-
ples, and therefore may have produced biased estimates of effect sizes,
and lacked power to detect potentially important differences be-
tween transdiagnostic treatments and control conditions. To ad-
dress these uncertainties, we conducted a systematic review and
meta-analysis to synthesise the evidence from studies evaluating
transdiagnostic psychological treatments for adult depressive and
anxiety disorders.1.1. Overview of existing transdiagnostic treatments for anxiety and
depressive disorders
The transdiagnostic treatments that have been evaluated to-date for
anxiety and depressive disorders tend to fall into two broad approaches.
The ﬁrst approach, which has beenmost researched, is broad-spectrum
transdiagnostic CBT (TD-CBT) interventionswhich target either hetero-
geneous anxiety disorders (e.g., Norton, 2008), or anxiety and depres-
sion (e.g., McEvoy & Nathan, 2007). TD-CBT protocols are informed by
cognitive and behavioural models of emotional disorders (Barlow,
2000; Beck, 1979; Norton, 2006) and apply a core set of generic CBT-
based treatment principles and techniques (e.g., graded exposure and
cognitive restructuring) to target the common processes underlying
anxiety and depression, rather than targeting the symptoms of speciﬁc
disorders. In contrast to this traditional CBT-based transdiagnostic
approach, there has also been increasing interest in “third wave” or
“new wave” behavioural and cognitive behavioural therapies such as
acceptance- and mindfulness-based interventions for the transdiagnostic
treatment of anxiety and depressive disorders (for a review of terminolo-
gy see Hofmann, Sawyer,Witt, & Oh, 2010). Unlike traditional CBT, which
aims to modify dysfunctional cognitions, behaviours and emotions,
acceptance- and mindfulness-based interventions aim to change a
person's perspective on, and relationship with their cognitions and emo-
tions. This process is facilitated through mindfulness, non-judgemental
awareness, and acceptance of psychological experiences.
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TD-CBT interventions have now been evaluated in group (anxiety
and depression: McEvoy & Nathan, 2007; anxiety: Norton, 2008), indi-
vidual (Arch et al., 2012), computerised (anxiety and depression:
Proudfoot et al., 2004) and online delivery formats (mixed anxiety
disorders: Johnston, Titov, Andrews, Spence, & Dear, 2011; anxiety
and depression: Titov et al., 2011). While it is still unclear which deliv-
ery format leads to superior outcomes, these studies have foundmoder-
ate to large uncontrolled effect sizes (ESs) for reductions in anxiety
symptoms (e.g., d = 1.68), depression and functional impairment
(e.g., Norton, 2008). In randomised controlled trials (RCTs) TD-CBT
has been shown to be more effective compared to waitlist control
(WLC) in group-format (controlled between-group ES: d = .50)
(Erickson, Janeck, & Tallman, 2007) and online delivery (Johnston
et al., 2011). However, there have been few RCTs comparing TD-
CBT with attention control conditions or other psychological treatments,
and those conducted give a more modest account of the impact of TD-
CBT. For example, although Norton (2012) found lower drop-out rates
during group TD-CBT, there were no signiﬁcant differences in anxiety
severity at post-treatment compared to relaxation training.
In addition, there is also discrepancy in the literature of existing RCTs
regarding how effective TD-CBT treatments are compared to disorder-
speciﬁc CBT treatments. For example, in one RCT, Craske et al. (2007)
showed that a disorder-speciﬁc programme of group plus individual
CBT sessions thatwas targeted solely at a patient's primary panic disorder
was more effective than a CBT protocol that targeted both the primary
panic disorder and comorbid disorders (e.g., depression). In contrast, in
another RCT, Norton and Barrera (2012) found no signiﬁcant differences
betweengroup-based TD-CBT anddisorder-speciﬁc groupCBT for anxiety
disorders. The latter studywas likely to be underpowered to detect statis-
tically signiﬁcant differences between the two treatment approaches. Our
aim was to use meta-analytic techniques to combine the results across
multiple RCTs comparing transdiagnostic to disorder-speciﬁc treatments.
By combining the results of individual trials, meta-analysis has the poten-
tial to increase the power to detect differences across these treatment
approaches.
In addition to broad-spectrum TD-CBT, other variations to TD-CBT
have been developed and evaluated. For example, Barlow and col-
leagues' Uniﬁed Protocol for Transdiagnostic Treatment of Emotional Dis-
orders (UP) (Ellard, Fairholme, Boisseau, Farchione, & Barlow, 2010) is
a transdiagnostic emotion-focused CBT-based intervention which aims
to improve emotional awareness and emotion regulation skills, facili-
tate cognitive and emotional ﬂexibility, and reduce avoidance and
maladaptive emotion-driven behaviours. The UP has been demonstrated
to lead to robust effects on anxiety and depression symptoms in two un-
controlled trials (Ellard et al., 2010;Wilamowska et al., 2010), and ismore
effective than a wait list control (WLC) in reducing anxiety (controlled
between-groupESs: 0.56 on the BAI, and 1.39 on the clinician severity rat-
ings of (co) principal diagnosis), and depression (controlled between-
group ESs: 1.11 on the BDI-II) (Farchione et al., 2012). Another variation
of TD-CBT is group-based false safety behaviour elimination therapy
(F-SET), which focuses solely on the reduction of transdiagnostic safety
seeking behaviours and safety signals. F-SET has been shown to have
large effects in the reduction of both self-reported and clinician-rated
anxiety severity (uncontrolled pre- to post-treatment ESs: d= 0.8–1.1),
moderate effects for depression (uncontrolled ES: d= .73), and medium
to large between group effect sizes compared to WLC on anxiety out-
comes at post-treatment (controlled between-group ES: d= .77), with
gains maintained up to 6 months (Schmidt et al., 2012).
1.3. Transdiagnostic mindfulness- and acceptance-based treatments
While there have been fewer evaluations of transdiagnostic
mindfulness- and acceptance-based treatments, results suggest that
they provide a viable and effective treatment option for emotionaldisorders. For example, Kabat-Zinn and colleagues (Kabat-Zinn et al.,
1992; Miller, Fletcher, & Kabat-Zinn, 1995), and more recently, Arch and
colleagues (Arch et al., 2013) have evaluated the impact of mindfulness-
based stress reduction (MBSR) with mixed samples of participants with
emotional disorders. MBSR is a group-based treatment that combines
psychoeducation with yoga and intensive guided mindfulness-based
meditation practices (e.g., body scan, formal sitting meditation). Kabat-
Zinn et al. (1992) demonstrated large uncontrolled ESs (0.88 on the
BAI) for reduction in anxiety symptoms followingMBSR, that weremain-
tained three years post-treatment (Miller et al., 1995). More recently,
Arch et al. (2013) compared MBSR with TD-CBT in an RCT, and found
that both MBSR and TD-CBT led to large reductions in the severity of pri-
mary anxiety diagnoses, worry, anxious arousal and depression symp-
toms. Although there were no signiﬁcant overall differences between
MBSR and TD-CBT, there were small effect sizes in favour of MBSR for
the severity of primary diagnoses andworry frequency at follow-up (con-
trolled between-group ES: d= .29) and in favour of TD-CBT (controlled
between-group ES: d= .31) for reducing anxious arousal. These results
indicate that MBSR provides an efﬁcacious treatment option for people
withmultiple emotional disorders (Arch et al., 2013), andmay have com-
parable effects to TD-CBT.
In another recent RCT, Arch et al. (Arch et al., 2012) compared the ef-
ﬁcacy of individual TD-CBT to individual acceptance and commitment
therapy (ACT). ACT (Hayes, Strosahl, &Wilson, 1999) is a psychological
therapy that combines psychoeducation and experiential exercises that
encourage mental ﬂexibility, cognitive defusion, mindfulness and ac-
ceptance of experiences and the reduction of experiential avoidance.
ACT interventions also aim to reduce experiential avoidance by promot-
ing active engagement in activities and behaviours that are done in pur-
suit of ones goals and personal values. The authors did not ﬁnd any
signiﬁcant differences between individual TD-CBT compared to ACT at
post-treatment, likely due to lack of power. However, there was a
small tomedium effect in favour of TD-CBT for improvements in quality
of life (d= .42), and a large effect for lower primary disorder severity
ratings at 12 months post-treatment for the ACT group (d = 1.10, for
the completer sample only) that did not reach signiﬁcance. Unfortu-
nately, therewere too few participants to detect whether CBT conferred
signiﬁcant beneﬁt over ACT or vice versa. Our aim was to combine the
results across individual trials using meta-analysis to shed light on
whether the type of transdiagnostic treatment inﬂuences outcomes.1.4. Previous systematic reviews and meta-analyses of transdiagnostic
psychological treatments and gaps in the existing literature
To date, there have been no previous attempts to systematically re-
view the full set of transdiagnostic psychological treatments for anxiety
and depressive disorders, beyond CBT delivered face-to-face. There has
been one narrative review of transdiagnostic treatments for depression
and anxiety disorders (McEvoy et al., 2009), and two meta-analyses of
transdiagnostic interventions, both restricting their focus to face-to-
face CBT protocols for anxiety disorders (Norton & Philipp, 2008;
Reinholt & Krogh, 2014). The ﬁrst meta-analytic review published by
Norton and Philipp (2008) found large mean uncontrolled effect sizes
for pre- to post-treatment reductions in anxiety (d = 1.29, 95%CI:
0.66–1.93). However, they only examined the uncontrolled effect sizes
because of the lack of available evaluations that included comparison
control conditions at the time of review. In a more recent evaluation,
Reinholt and Krogh (2014) carried out a meta-analysis of 11 RCTs
of TD-CBT protocols for anxiety disorders that had been published
prior to June 2013, and found that TD-CBT outperformed WLC and
treatment-as-usual (TAU) control conditions, with a medium overall
difference between groups in anxiety severity at post-treatment
(d = .68, 95%CI: .45–.90). The results suggested that RCTs using WLC
conditions had larger effect sizes (controlled ES: d = 1.00) compared
to those that used TAU control conditions (controlled ES: d= .28).
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efﬁcacy of TD-CBT protocols in reducing anxiety severity, but there are
questions that await further investigation. Because Reinholt and Krogh
(2014) included anxiety severity as their sole outcome measure, it re-
mains unclear whether transdiagnostic treatments have differential ef-
fects on anxiety compared to depression, andwhat impact they have on
quality of life. Measurement of quality of life is particularly important be-
cause quality of life is a standardmeasure usednot only for the calculation
of QALYs (quality-adjusted-life-years), but in health economic analyses
(e.g., cost utility analyses). The degree to which gains are maintained
following transdiagnostic treatments also awaits further evaluation. In
addition, both of the meta-analyses restricted their analysis to CBT inter-
ventions thatwere delivered face-to-face. Amore inclusive systematic re-
view and meta-analysis is now needed that comprehensively reviews:
(i) the full set of transdiagnostic treatments for emotional disorders, in-
cluding CBT aswell as “thirdwave”ACT andmindfulness-based interven-
tions, and (ii) treatments that are delivered across different formats,
including face-to-face group, individual, and computerised treatments.
Understandingwhether the type of transdiagnostic treatment and the de-
livery format have an impact on outcomes has the potential to inform
both clinical practice and future treatment developments in this area. In
addition, Reinholt and Krogh (2014) only explored how transdiagnostic
treatments compare toWLC and TAU control conditions. Further research
is therefore needed to explore how transdiagnostic treatments perform
on average relative to no-treatment/WLC controls versus TAU, as well as
against other attention control conditions (such as relaxation training or
psychological placebo), and disorder-speciﬁc treatments.
2. Aim/objectives
The aimof this reviewwas to provide a comprehensive review of the
published studies evaluating transdiagnostic psychological treatments
for adults with depression and/or anxiety disorders. In conducting this
review, we aimed to answer three main questions: (1) what are the
overall effects of transdiagnostic treatments on depression, anxiety
and quality of life?; (2) what is the relative efﬁcacy of transdiagnostic
treatments versus various control conditions (WLC, TAU, attention con-
trol and disorder-speciﬁc treatments)?; and (3) what is the impact of
potential moderators of treatment effect including type of treatment
and delivery format?. Theﬁnal aim of this reviewwas to provide recom-
mendations for future research and treatment development.
3. Methods
3.1. Protocol and registration
We followed the PRISMA guidelines for reporting of this systematic
review (Moher, Liberati, Tetzlaff, Altman, & The, 2009). This reviewpro-
tocol was developed following the procedures outlined in the Cochrane
Handbook for systematic reviews (Higgins & Green, 2011), and the pro-
tocol was registered with PROSPERO2 [CRD42014010469].
3.2. Inclusion/eligibility criteria
(i) Types of participants: We included studies in which participants
were adults (18 years and older), who met DSM or ICD criteria
for a primary diagnosis of an anxiety or depressive disorder or
mixed anxiety and depression, established by a formal validated
diagnostic interview. Because the search protocol was initially de-
velopedwith DSM-IV-TR diagnostic categories inmind (American
Psychiatric Association, 2000), we included posttraumatic stress2 http://www.crd.york.ac.uk/PROSPERO/index.asp.disorder (PTSD) and acute stress disorder (ASD) as anxiety disor-
ders, although they are now classiﬁed as trauma and stressor-
related disorders in DSM-5 (American Psychiatric Association,
2013). Depressive disorders included major depressive disorder
(MDD), dysthymic disorder, and minor depression. For the pur-
poses of determining whether studies met our inclusion criteria,
depressive disorders were classiﬁed as one disorder category
(e.g., dysthymic disorder and major depression were grouped to-
gether under the category of ‘depressive disorder/depression’).
(ii) Types of interventions: We included studies of manualised psycho-
logical treatments for adults that lasted for 2 or more sessions and
targeted: (i) two or more anxiety disorders; (ii) at least one
anxiety disorder together with a depressive disorder/depression.
Face-to-face clinician-delivered treatments were included.
Internet- or computer-delivered treatments were included
only if they were clinician-guided. Clinician-guided internet-
or computer-delivered treatments were deﬁned as treat-
ments that involved having some form of email and/or tele-
phone contact with a therapist, clinician or support person
during the treatment or intervention period; that is, the clini-
cian contact was not just restricted to pre-treatment assessment
interviews.
(iii) Types of comparisons and outcomes: Studies were included that
reported at least one validated self-report measure of anxiety
or depression at both baseline and post-treatment, enabling us
to calculate at minimum, the average uncontrolled effect size
on primary outcome measures. Given we were interested in ex-
amining the maintenance of gains following treatment; we
were also interested in examining outcomes at short-term
follow-up (deﬁned as up to 6 months post-treatment). We
also included randomised trials in which the effects of
transdiagnostic treatment were compared with either: (a) a
no-treatment (WLC) condition; (b) a care-as-usual, or
treatment-as-usual control condition (TAU); (c) another con-
trol psychological treatment (e.g., relaxation) or attention
control condition; or (d) a disorder-speciﬁc psychological treat-
ment. This enabled us to calculate between-groups effect sizes
based on comparisons between conditions at post-treatment. Di-
agnostic status was not used as an outcome variable because
there were too few studies that reported this variable at post-
treatment or follow-up.
(iv) Types of study design: We included studies published in En-
glish in a peer-reviewed journal up to February 28, 2014. We
included all uncontrolled (open) trials which involved a pre–
post-study design, or randomised controlled trials comparing
transdiagnostic interventions to a control condition. RCTs
with multiple control conditions were also included as long
as all of the other inclusion criteria were met. One of the pur-
poses of this study was to conduct a comprehensive overview
and examination of the available literature. Therefore, we
chose to include uncontrolled trials as well as RCTs, rather
than restricting our analysis to the available RCTs.
3.3. Excluded studies
We excluded studies in which the psychological treatment was not
manualised, studies inwhich therewas insufﬁcient data reported to cal-
culate effect sizes andwherewe could not obtain those data, and studies
that focused on populations under age 18. Case studies and case series
were also excluded. Finally, studies with mixed samples with psychotic
disorders, personality disorders, and substance use disorders were ex-
cluded. Treatment protocols that involved combinations of pharmaco-
logical and psychological interventions were excluded. Entirely self-
guided computerised or internet-delivered treatments were also
excluded.
3 We conducted a sensitivity analysis by recalculating the estimated effect using corre-
lation values of 0.25 and 0.75 to explorewhether changing this imputed value affected the
overall effect size estimate. There were no substantial differences in the effect size esti-
mates when we used within-group correlations of 0.25 or 0.75 instead of 0.5, with the
largest difference between estimates being .02.
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To identify studies for possible inclusion, we conducted comprehen-
sive systematic searches of the electronic databases PSYCInfo, and
PubMed up to 28 February 2014 (see Appendix A for our electronic
search strategy for PSYCInfo). To broaden the search criteria and maxi-
mise the sensitivity of our search, we combined terms indicative of anx-
iety, depression, mixed anxiety and depression, anxious depression, as
well as various anxiety and depressive disorders with the terms
‘transdiagnostic’ and a large range of psychotherapies such as vari-
ous forms of CBT, stress management, mindfulness-based therapies
(e.g., MBSR), ACT, attention training, metacognitive therapy (MCT)
and psychotherapy. We searched for a range of study types includ-
ing uncontrolled open trials, effectiveness studies and randomised
trials. We also searched the references lists of relevant manuscripts
and previous reviews of this literature, to identify additional studies
that met our inclusion criteria.
3.5. Study selection
The ﬁrst author (JN) initially screened all of the titles and abstracts
for all studies to determine their relevance to this study. Studies that
could be immediately excluded on the basis of the title and abstract
were discarded. For the remaining references, full text manuscripts
were reviewed for more comprehensive evaluation of the study inclu-
sion criteria. Both JN and AM independently read each full text to assess
eligibility for inclusion, and disagreements were resolved through dis-
cussion, and consultation with TD.
3.6. Data extraction and management
Data regardingmethodology and outcomemeasures were extracted
into a Microsoft Excel spread sheet by JN (which was independently
checked by a research assistant), before being transferred to Com-
prehensive Meta-Analysis (version 2.0; Biostat, Inc.) for the meta-
analysis. The following information from each study was extracted: au-
thors, year of publication, setting, diagnostic assessmentmeasure,mean
age, gender (proportion female), type of intervention (e.g., CBT, ACT),
delivery format (face-to-face individual, internet/computer, and face-
to-face group), duration of intervention, and attrition rates. Outcome
data for the primary and secondary outcome measures assessing anxi-
ety, depression, and quality of life were also extracted. For multiple re-
ports of the same study, we combined the outcome measures and
considered them as one study.
3.7. Primary outcomes
1. Symptoms of anxiety, according to continuous symptom measures
such as the Beck Anxiety Inventory (BAI) (Beck & Steer, 1996), Gen-
eralised Anxiety Disorder 7-item scale (GAD-7) (Spitzer, Kroenke,
Williams, & Lowe, 2006), or the Anxiety subscale of the Depression
Anxiety Stress Scale (DASS-21) anxiety subscale (Lovibond &
Lovibond, 1995).
2. Symptoms of depression, according to continuous symptommeasures
such as the Beck Depression Inventory (BDI, Beck, Ward, Mendelson,
Mock, & Erbaugh, 1961), Beck Depression Inventory Second edition
(BDI-II, Beck, Steer, & Brown, 1996), the nine-item Patient Health
Questionnaire (PHQ-9: Kroenke, Spitzer, & Williams, 2001) or the
Depression subscale of the DASS-21 (Lovibond & Lovibond, 1995).
3. Quality of life according to general measures of quality of life or func-
tional impairment including the Euro-Qol (Euroqol Group, 1990) or
the SF-12 (Ware, Kosinski, & Keller, 1996).
We extracted and analysed outcome data on self-reported symp-
toms of depression, anxiety and quality of life at post-treatment and
follow-up. There was not enough information reported in the studiesto analyse diagnostic status following treatment. Because many of the
studies used more than one instrument to measure anxiety (or depres-
sion) we used the primary outcome as reported by the study investiga-
tors, or if absent, we used the most frequently used measures across
studies (BAI, GAD-7, and BDI, PHQ-9, DASS-21 depression subscale).
All included studies reported means and standard deviations at post-
intervention, allowing us to calculate the effect size directly, but there
were only 24 studies that reported at least one outcome measure at 3-
to 6-months follow-up.
3.8. Risk of bias in individual studies
We assessed the quality and risk of bias of included RCTs using the
‘Risk of Bias’ tool, developed by the Cochrane Collaboration (Higgins &
Green, 2011). This tool allowed us to assess possible sources of risk in
RCTs, including: (1) allocation sequence (the method used to generate
the allocation sequence is provided in sufﬁcient detail to allow an as-
sessment of whether it should produce comparable groups), (2) alloca-
tion concealment (the method used to conceal the allocation sequence
is given in sufﬁcient detail to determine whether intervention alloca-
tions could have been foreseen in advance of, or during, enrolment),
(3) blinding of participants, personnel and outcome assessors (all
measures used to blind outcome assessors from knowledge of which in-
tervention a participant received), (4) incomplete outcome data (assess-
ment of the completeness of outcome data from each main outcome
including attrition and exclusions, and whether all randomised partici-
pants were included in the analyses). The assessment of study quality
was conducted by two independent reviewers (JN andAM) and disagree-
ments were resolved via discussion. See Table 1 for quality ratings of in-
cluded controlled trials.
3.9. Statistical analyses
3.9.1. Calculation of effect sizes: changes on primary outcome measures
between pre- and post-treatment, and pre-treatment and follow-up
To examine the within-group effect (uncontrolled effect size) of
transdiagnostic psychological treatments, for each treatment we calcu-
lated the effect size referring to the difference between baseline and
post-treatment (or between baseline and follow-up), divided by pooled
standard deviation on eachprimary outcomemeasure, and the95% con-
ﬁdence intervals around the effect sizes. Effect sizes were also adjusted
to address small sample sizes, according to the procedures outlined in
Hedges and Olin (1985, or Hedges g). Because the baseline and post-
treatment values are not independent from each other, the correlation
between time points was required, but most studies did not include
the correlation within the body of the manuscript. In the absence of
the correlation between time-points, we used a conservative value of
0.50 (Balk, Earley, Patel, Trikalinos, & Dahabreh, 2012).3
3.9.2. Calculation of effect sizes: transdiagnostic treatments versus controls
For each comparison between a transdiagnostic psychological treat-
ment and a control condition, we calculated the effect size (Hedges g)
referring to the difference between the two groups at post-treatment
(standardised mean difference) and the 95% conﬁdence intervals
around the effect sizes. Effect sizes were calculated by subtracting the
average score of the transdiagnostic treatment at post-treatment from
the average score for the control group, and dividing the result by the
pooled standard deviation of the two groups. Effect sizes of 0.2, 0.5
and 0.8 refer to small, moderate and large effect sizes respectively
(Cohen, 1988). Effect sizes were also adjusted to address small sample
4 These studies were not included in the calculation of effect sizes comparing
transdiagnostic treatments versus control groups, as they did not fall within the control
group categories that were the focus of this review.
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To calculate pooledmean effect sizes, we used the programme Com-
prehensiveMeta-Analysis (version 2.0, Biostat Inc.). Given that Reinholt
and Krogh (2014) found evidence of heterogeneity, we similarly ex-
pected substantial heterogeneity amongst the interventions, and there-
fore calculated the mean effect sizes using a random effects model. The
random effects model assumes that the true effect size varies from one
study to the next, and that the studies in our analysis represent a ran-
dom sample of effect sizes that could have been observed. The summary
effect is our estimate of the mean of these effects (Borenstein, Hedges,
Higgins, & Rothstein, 2009).
3.10. Subgroup analyses
To assess the differences between subgroups (treatment type: CBT
vs. mindfulness/acceptance-based treatments; treatment format: indi-
vidual, group and computer/internet interventions), and the differences
in outcomes on anxiety versus depressionmeasures,we conducted sub-
group analyses using themixed effect model approachwith the dataset
that included all studies with pre- to post-treatment data. In this model,
a random-effects model is used to pool studies within subgroups
(e.g., individual treatment), and we test for signiﬁcant differences be-
tween subgroups using a ﬁxed-effects model.
3.11. Testing homogeneity
To test the homogeneity of effect sizes, we calculated the I2 statistic,
which is an indicator of heterogeneity across effect sizes, and is provid-
ed as a score in percentages. A value of 0% indicates no heterogeneity,
whereas scores of 25%, 50% and 75% indicate low, moderate, and high
heterogeneity, respectively.
3.12. Risk of bias across studies
3.12.1. Testing for publication bias and dealing with publication bias
To test for publication bias, we inspected the funnel plot on the
primary outcome measures (for depression, anxiety and quality of life
measures respectively) (Egger, Davey Smith, Schneider, & Minder,
1997). In addition, we also conducted Duval and Tweedie's Trim and
Fill procedure (Duval & Tweedie, 2000a, 2000b) within Comprehensive
Meta-Analysis, which yields an adjusted effect size that takes into
account the publication bias observed within the funnel plot. This pro-
cedure corrects for the variance of the effects and provides a best esti-
mate of the unbiased effect size.
4. Results
4.1. Study selection
Fig. 1 presents the ﬂowchart describing the inclusion of studies. A
total of 10958 titles and abstracts were examined. 10589 were rejected
at title and abstract, and a further 323 were rejected after the entire ar-
ticle was reviewed. This left a total of 47 studies (from 46 articles) that
were analysed. Of these, 31 were RCTs, 15 were uncontrolled trials, and
one was a non-randomised trial.
4.2. Study characteristics
Characteristics of the included studies are found in Table 1. Because
some studies reported evaluations of either separate groups undergoing
the same treatment (e.g., results for immediate and delayed treatment
undergoing internet-delivered CBT [iCBT], Titov, Andrews, Johnston,
Robinson, & Spence, 2010), or different transdiagnostic treatments
(e.g., results for ACT and CBT, see Arch et al., 2012), we were able to in-
clude 50 studies in which 1865 patients participated to calculate theaverage uncontrolled effects of transdiagnostic treatments between
pre- and post-treatment. The majority of these examined TD-CBT or
variants of TD-CBT such as behavioural activation combinedwith expo-
sure therapy, and anxiety management with virtual reality exposure
(n = 40). Seven studied mindfulness/acceptance-based interventions
(of which onewas ACT) and three evaluated other forms of psychother-
apy (e.g., short term psychodynamic psychotherapy). Five studies eval-
uated TD-CBT in older adult samples only (N55 years, mean age =
69 years), and the remainder included working age adults over
18 years of age (mean age=39 years). The sampleswere predominant-
ly comprised of females (mean proportion of females = 63%). With re-
gard to treatment format, 17 evaluated computer/internet, 18 face-to-
face group, and 17 face-to-face individual treatment format. In most
studies of face-to-face therapies, the treatments had 12 or fewer treat-
ment sessions (range 6–40 sessions). Rates of attrition varied across
studies from 0% to 56% (see Table 1).
Of the 31 RCTs, therewere 27 studies (reporting 29 comparisons) in-
cluded in the meta-analysis comparing transdiagnostic treatments
(n=1109) to control conditions (n=992). The studies ranged in sam-
ple size from10 to 121per condition. For the control conditions, 12 used
WLC condition, 4 used treatment-as-usual (TAU) or (enhanced) usual
care control conditions, two used discussion forums, one online clinical
support, two used relaxation training, one supportive counselling, three
used psychoeducation as a control condition, and four used disorder-
speciﬁc treatments. In addition, there were two studies (with 233
participants altogether) which compared two alternative types of
transdiagnostic interventions (TD-CBT versus ACT, group MBSR versus
group TD-CBT). There was also one randomised comparison between
computerised versus face-to-face TD-CBT, and another study that used
antidepressant medications and pill placebo as their control condition.44.3. Pre-treatment diagnostic assessment and outcome measures
The majority of the studies administered the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) (First, Spitzer, Gibbons,
& Williams, 1996), the Anxiety Disorders Interview Schedule (ADIS-
IV) (Brown, Dinardo, & Barlow, 1994) or the Mini International Neuro-
psychiatric Interview version 5.0.0 (MINI) (Sheehan et al., 1998) to ob-
tain a diagnostic assessment at pre-treatment. A wide range of outcome
measures were used to assess self-reported anxiety and depressive
symptoms and quality of life, with the most common the BAI, the
BDI (or BDI-II), and the QOLI. Only 39 out of 50 studies that reported
pre- to post-treatment effects incorporated quality of life assess-
ment measures.4.4. Risk of bias within randomised controlled trials
The methodological quality of the studies reporting RCTs varied
widely (see Table 1). Twenty one (68%) reported adequate generation
of random sequencing, 14 (45%) reported adequately concealing
group allocation, and 21 (68%) reported appropriate blinding of out-
come assessments. Twenty four (78%) studies were coded as at low
risk of bias for incomplete outcome data, and 30 studies (97%) were
found to have low risk of bias for selective reporting of outcomes. Over-
all, only seven studies were classiﬁed by reviewers as at low risk of bias
on all ﬁve measures of risk of bias. Thirteen studies were low risk on
four, 5 on three, 4 on two, and 2 were low risk of bias on either none
or only one measure.
Table 1
Characteristics of studies included in the meta-analysis evaluating transdiagnostic treatments for anxiety and/or depression.
Study Country Participants Sample Design Intervention Clinician Diagnostic
measure
Measures Attrition Qual
Anderson
et al.
(2005)
USA DSM-IV Panic/Ag or
SocPhob, with public
speaking main fear
Community, mean
age not reported, 80%
female
Open trial:
AM + VRE: 10
AM+ VRE: 12 AM+ 4 VR
(individual)
Psychologist SCID-IV PRCS, SSPS-pos,
SSPS-neg, PRCA
None n/a
Andersson
et al.
(2011)
Sweden DSM-IV anxiety
disorder
Community, mean
age: 38 years, 85%
female
Open trial: iCBT: 27 iCBT: 10 modules over 10 weeks Clinical psychology
trainees
SCID-IV CORE-OM, MADRS-S,
BAI, QOLI
65% completed
b100% of
modules
n/a
Arch et al.
(2013)
USA DSM-IV Panic/Ag, OCD,
SocPhob, GAD, PTSD
Community, mean
age: 46 years, 17%
female
RCT:
GMBSR: 45
GCBT: 60
GMBSR: 9 × 90 min (group) + 1
× 3 h (retreat)
GCBT: 10 × 90 min (group)
Clinical
psychologist,
psychiatric nurse
MINI CSR, PSWQ, MASQ-AA,
BDI-II
GMBSR: 56%
GCBT: 43%
− ?−−−
Arch et al.
(2012)
USA DSM-IV anxiety
disorder
Community, mean
age: 38 years, 52%
female
RCT:
CBT: 71
ACT: 57
12 × 60 min (individual) Doctoral level
therapists
ADIS-IV ADIS CSR, ASI, PSWQ, FQ,
QOLI, AAQ,
CBT: 32%
ACT: 35%
−+−−−
Barlow et al.
(1984)
USA DSM-III panic disorder
or GAD
Community, mean
age: 38 years, 35%
female
RCT:
CBT/biofeedback/RT:
10
WLC: 10
CBT: 18 sessions (individual) Doctoral level
therapists,
graduate students
ADIS-III STAI, BDI, CSR, PSC CBT: 0 ? ? +−−
Barrowclough
et al.
(2001)
UK Age over 55 and
DSM-IV Panic/Ag,
SocPhob, GAD, ADNOS
Community, mean
age: 72 years, 77%
female
RCT:
CBT: 27
SC: 28
CBT: 8–12 × 60 min (individual)
SC: 8–12 × 60 min sessions
(individual)
CBT: doctoral level
psychologist
SC: counsellor
SCID-IV BAI, STAI-T, HARS-A, BDI,
GDS
CBT: 11%
SC: 4%
− ?−−−
Berger et al.
(2014)
Switzerland,
Germany,
Austria
DSM-IV GAD, SocPhob,
Panic/Ag
Community, mean
age: 35 years, 56%
female
RCT:TD-
iCBT: 44,DS-iCBT,
WLC: 44
TD-CBT and DS-CBT: 8 sessions
over 8 weeks
Master of Science
students and
psychologist
SCID-IV BAI, BDI-II, BSI, SPS, SIAS,
MI, PSWQ, BSQ, CAQ
TD-iCBT: 9.1%
disorder speciﬁc
iCBT: 11.3%,
WLC: 9.1%
−− ?−−
Brenes et al.
(2012)
USA Age over 60, DSM-IV
GAD, Panic/Ag, ADNOS
Community, mean
age: 69 years, 83%
female
RCT:
T-CBT: 30
Psychoeducation: 30
T-CBT: 8 chapters over 8 sessions
+ 4 booster sessions
Doctoral level
students and
masters level
therapist
SCID-IV PSWQ, STAI-T, ASI, BDI,
HARS-A, SF-36
T-CBT: 10%
Psychoeducation:
3%
? ?−−−
Bressi et al.
(2010)
Italy DSM-IV TR depressive
or anxiety disorder
Community, mean
age: 37 years, 77%
female
RCT:
STPP: 30
TAU: 30
STPP: 40 × 45 minute sessions Psychiatrists SCID-IV SCL-90-R, CGI, IIP STPP: 20%
TAU: 20%
−−−−−
Carlbring
et al.
(2011)
Sweden DSM-IV anxiety
disorder (including
ADNOS)
Community, mean
age: 39 years, 76%
female
RCT:
iCBT: 27
Online forum: 27
iCBT: 6–10 modules over 10
weeks
Clinical psychology
students
SCID-IV CORE-OM, MADRS-S,
BAI, QOLI
M = 7.96
modules
completed
−−−−−
Craske et al.
(2007)
USA DSM-IV panic disorder Community, mean
age: 39 years, 60%
female
RCT:TD-
CBT: 33DS-
CBT: 32
DS-CBT (panic focus): 12 × 120
min (group + 6 × 60 min
individual)
TD-CBT: 12 × 120 min (group:
panic focus) + 6 × 60 min
(individual: comorbid disorder
focus)
Doctoral students
and postdoctoral
fellows
ADIS-IV ASI, FQ, CSR, BSI, SSS, BATs DS-CBT: 18%
TD-CBT: 13%
−+−−−
Cyranowski
et al.
(2005)
USA DSM-IV MDD +
Panic/Ag
Community, mean
age: 37 years, 83%
female
Open trial:
IPT: 18
IPT: 16–24 individual sessions Not reported SCID-IV HRSD, HARS, BDI, BAI, WLESQ IPT: 28% n/a
Dear et al.
(2011)
Australia DSM-IV MDD, GAD,
Panic/Ag, or SocPhob
Community, mean
age: 44 years, 78%
female
Open trial: iCBT: 32 iCBT: 5 lessons over 8 weeks Clinical
psychologists
MINI DASS-21, PHQ-9, PSWQ,
PDSS-SR, SP-12, GAD-7, K-10,
SDS, NEO
iCBT: 19% n/a
Ellard et al.
(2010)
USA Primary DSM-IV
anxiety disorder
Community, mean
age: 30 years, 56%
female
Open trial:
Study 1: 24
Study 2: 18
Study 1: 8–15 × 60 min individual
sessions
Study 2: 12–18 × 60 min
individual sessions
Doctoral students
and doctoral level
psychologist
ADIS-IV BDI-II, BAI, PANAS-PA,
PANAS-NA, OCI-R, PDSS-SR,
PSWQ, SIAS, WSAS
Study 1: 8%
Study 2: 17%
n/a
Erickson et al.
(2007)
Canada DSM-IV PTSD, GAD,
Panic/Ag, OCD,
SocPhob
Community, mean
age: 41 years, 64%
female
RCT:
CBT: 73
WLC: 79
11 × 120 minute sessions Doctoral students SCID-IV GAF, BAI, BDI-II, ASI CBT: 41% +++++
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Farchione
et al.
(2012)
USA DSM-IV anxiety
disorder
Community, mean
age: 30 years, 59%
female
RCT:
CBT: 26
WLC: 11
18 × 60 minute sessions Doctoral students
and doctoral level
therapists
ADIS-IV HARS, HRSD, SIGH-A, SIGH-D,
BDI-II, BAI, PANAS-PA, PANAS-NA,
PSWQ, SIAS, PDSS-SR, YBOCS, WSAS
CBT: 15% ? ?−−−
Jakupcak
et al.
(2010)
USA DSM-IV PTSD and
MDD
Community, mean
age: 28 years, 0%
female
Open trial:
BA: 7
8 × 60 minute sessions Not reported CAPS, SCID-IV PCL-M, BDI-II, QOLI 29% n/a
Johansson
et al.
(2012)
Sweden MDD + comorbid
symptoms
Community, mean
age: 45 years, 71%
female
RCT:
iCBT (tailored):
36DS-
iCBT: 37
Online discussion
forum: 42
iCBT (tailored):
8 modules over 10 weeks
iCBT (DS): 8–10 chapters over 10
weeks
Masters level
psychologists
SCID-IV BDI-II, MADRS-S, BAI, QOLI iCBT (tailored)
19%DS-
iCBT: 23% did not
complete all
modules
−−−−−
Johansson
et al.
(2013)
Sweden DSM-IV MDD,
SocPhob, Panic, GAD,
DDNOS, ADNOS
Community, mean
age: 45 years, 82%
female
RCT: I-AFPP: 50,
online support: 50
I-AFPP: 8 modules over 10 weeks Masters level
students
MINI
(telephone)
GAD-7, PHQ-9 I-AFPP: 16%,
Online Support:
0%
−−−−−
Johnston
et al.
(2011)
Australia DSM-IV GAD, SocPhob,
Panic/Ag
Community, mean
age: 42 years, 59%
female
RCT:
iCBT-CO: 47
iCBT-CL: 46
WLC: 46
iCBT-CO and iCBT-CL: 8 lessons
over 10 weeks
iCBT-CO:
registered
psychologist
iCBT-CL: doctoral
level psychologist
MINI
(telephone)
GAD-7, DASS-21, PSWQ,
SIAS-6/SPS-6, PDSS-SR, PHQ-9, SDS
iCBT-CO: 26%
iCBT-CL: 24%
−−+−−
Kabat-Zinn
et al.
(1992)
USA DSM-III-R GAD,
Panic/Ag
Community, mean
age: 42 years, 59%
female
Open trial:
MBSR: 22
8 × 120 min group sessions (+7.5
hour intensive meditation
retreat)
Not reported SCID-III HARS-A, HARS-D, BAI, BDI, MI, FSS 0% n/a
Kenwright
et al.
(2004)
UK ICD-10 phobia or
Panic/Ag
Community, mean
age 46 years, 41%
female
Non-randomised
trial:
CCBT: 17
iCBT: 10
12 week ERP with clinician
assistance
Nurse WHO (1992)
interview
checklist for
ICD-10
FQ, WSAS, BDI 37% n/a
Kim et al.
(2009)
Republic of
Korea
DSM-IV GAD or
Panic/Ag
Community, mean
age: 39 years, 26%
female
RCT:
MBCT: 24
Psychoed: 22
MBCT: 8 × 90 m group sessions
Psychoed: 8 × 60 min group
sessions
Psychiatrist SCID-IV HAM-A, BAI, SCL-90-R, HAM-D, BDI RCT:
MBCT: 12.5%
Psychoed: 9.1%
++−−−
Lee et al.
(2007)
South Korea DSM-IV GAD, or
Panic/Ag
Community, mean
age: 38 years, 35%
female
RCT:
MBSM: 24
Psychoeducation: 22
RCT:
MBSM: 8 × 60 min session
Psychoeducation: 8 × 60 min
session
MBSM: Psychiatrist
and meditation
specialist
Psychoeducation:
psychiatrist
SCID-IV HAM-A STAI, HAM-D BDI, SCL-90-R MBSM: 12%
Psychoeducation:
9%
? ?−+−
Liu et al.
(2007)
China Primary ICD-10
depression, GAD,
Panic/Ag, SocPhob,
OCD, MADD
Hospital clinic, mean
age: 43 years, 81%
female
RCT
PST: 84
CL: 85
TAU: 85
PST: 6 sessions over 16 weeks
CL: 16 weeks
TAU: 16 weeks
PST: psychologist,
social worker,
psychiatric nurse
CL: psychiatrist
CISR CISR, HRSD, SF-36, PST: 42%
CL: 20%
TAU: 19%
−+−−−
Marks et al.
(2004)
UK ICD-10 phobia or
Panic/Ag
Community, mean
age: 38 years, 69%
female
RCT:
CCBT: 37
CBT: 39
RT: 17
RCT:
6 × 60 min individual sessions
over 10 weeks
Nurse and
psychologist
WHO (1992)
interview
checklist for
ICD-10
FQ, WSAS CCBT: 43%
CBT: 26%
RT: 6%
−−−+−
McEvoy and
Nathan
(2007)
Australia DSM-IV Anxiety
disorder or affective
disorder
Community, mean
age: 35 years, 59%
female
Open trial:
GCBT: 143
11 × 120 min group sessions Masters or doctoral
level psychologists
MINI BDI-II, BAI M = 8.38
sessions attended
n/a
Newby et al.
(2013)
Australia DSM-IV GAD, MDD, or
mixed anxiety and
depression
Community, mean
age: 44 years, 78%
female
RCT:
iCBT: 46
WLC: 53
iCBT: 6 lessons over 10 weeks Doctoral level
psychologist
MINI
(telephone)
PHQ-9, GAD-7, K-10, BDI-II, PSWQ,
WHODAS-II
6.5% −−+−−
Nixon and
Nearmy
(2011)
Australia DSM-IV MDD and
PTSD
Community, mean
age: 45 years, 85%
female
Open trial:
BA + ERP: 20
12–16 × 60 min sessions Postgraduate
clinical
psychologists
trainee
CAPS and MINI CAPS, PDS, DASS-D, PTCI 30% n/a
Norton and
Barrera
(2012)
USA DSM-IV Panic/Ag,
SocPhob, GAD
Community, mean
age: 31 years, 50%
female
RCT:TD-
GCBT
(transdiagnostic):
23
GCBT
(disorder-spec): 23
12 × 120 m sessions Doctoral level
graduate students
ADIS-IV ADIS CSR, STAI, PDSS, SPDQ,
GADQ-IV, BDI
TD-GCBT:
22%DS-
GCBT: 39%
++−+−
Norton
(2008)
USA DSM-IV anxiety
disorder
Community, mean
age: 31 years, 56%
female
Open trial:
GCBT: 52
12 × 120 m sessions Doctoral level
graduate students
ADIS-IV STAI-S, M = 7 sessions
attended
n/a
(continued on next page) 99
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Table 1 (continued)
Study Country Participants Sample Design Intervention Clinician Diagnostic
measure
Measures Attrition Qual
Norton
(2012)
USA DSM-IV anxiety
disorder
Community, mean
age: 33 years, 62%
female
RCT:TD-
GCBT: 65
RT: 22
TD-GCBT: 12 × 120 m sessions
RT: 12 × 120 m sessions
Doctoral level
graduate students
ADIS-IV ADIS CSR, CGI, ADDQ, BAI, PDSS,
SPDQ, GAD-Q-IV, STAI-S
RCT:TD-
GCBT: 30%
RT: 57%
++−+−
Norton et al.
(2004)a
USA DSM-IV anxiety
disorder
Community, mean
age: 42 years, 61%
female
RCT:
GCBT: 12
WLC: 11
12 × 150 m (group) Doctoral level
graduate students
ADIS-IV DASS-42, MASQ GCBT: 25% ++++−
Patel et al.
(2003)
India ICD-10 common
mental disorders
Community, mean
age: 49 years, 81%
female
RCT:
CBT: 150
Medications: 150
Placebo: 150
CBT: up to 6 sessions Trained therapists CISR CISR, BDQ CBT: 12%
Medications: 11%
Placebo: 5%
−−−−−
Proudfoot
et al.
(2004)
UK ICD-10 depression,
mixed
anxiety/depression or
anxiety disorder
Community, mean
age: 44 years, 74%
female
RCT:
CCBT: 89
TAU: 78
CCBT: 9 sessions with nurse
guidance
Nurses CISR
(computerised)
BDI-II, BAI, WSAS CCBT: 33%
TAU: 30%
−−−−−
Proudfoot
et al.
(2003)
UK ICD-10 depression,
mixed
anxiety/depression or
anxiety disorder
Community, mean
age: 44 years, 74%
female
RCT:
CCBT: 146
TAU: 128
CCBT: 9 sessions with nurse
guidance
Nurses CISR
(computerised)
BDI-II, BAI, WSAS CCBT: 27%
TAU: 24%
−−−−−
Radley et al.
(1997)
UK DSM-IV anxiety
disorders
Community elderly
patients, mean age:
71 years, 100% female
Open trial:
GCBT: 9
GCBT: 7 × 90 min Psychiatrist,
clinical
psychologist and
psychiatric nurse
HADS N 10 HAD-A, HAM-A, GAS, STAI, FI, PSI,
CAQ, ELI
GCBT: 30% n/a
Ree and
Craigie
(2007)
Australia DSM-IV mood or
anxiety disorders
Private clinic, mean
age: 40 years, 77%
female
Open trial:
MBCT: 26
8 × 150 min Clinical
psychologist and
clinical psychology
trainee
SCID BDI, DASS-42 MBCT: 11% n/a
Schmidt et al.
(2012)
UK Primary DSM-IV
Panic/Ag, GAD,
SocPhob
Community, mean
age: 36 years, 72%
female
RCT:
F-SET: 57
WLC: 39
F-SET: 10 × 120 min s Masters or doctoral
level therapists
SCID-IV ASI, BDI-II, MI, SDS, SPRAS, CGI F-SET = 7% −−+−−
Titov et al.
(2011)
Australia DSM-IV GAD, SocPhob,
Panic/Ag
Community, mean
age: 44 years, 73%
female
RCT:
iCBT: 37
WLC: 38
8 lessons over 10 weeks Masters or doctoral
level clinical
psychologist
MINI
(telephone)
PSWQ, SPSQ, PDSS-SR, GAD-7,
PHQ-9, SDS, K-10, DASS-21, NEO
iCBT: 19% −−+−−
Titov et al.
(2010)
Australia DSM-IV GAD, Panic/Ag,
SocPhob, or MDD
Community, mean
age: 39 years, 68%
female
RCT:
iCBT: 40
WLC: 38
6 lessons over 10 weeks Masters or doctoral
level clinical
psychologist
MINI
(telephone)
PHQ-9, GAD-7, Social Phobia-12,
PDSS-SR, SDSK-10, BDI-II, PSWQ,
WHODAS-II
iCBT: 25% −−+−−
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Vollestadet al.
(2011)
Norway DSM-IV anxiety
disorder
Community, mean
age: 46 years, 17%
female
RCT:
MBSR: 39
WLC: 37
MBSR: 8 × 150 minute sessions
WLC:
Not reported MINI BAI, PSWQ, STAI, BDI-II, SCL-90 MBSR: 18% ? ?−−−
Westra et al.
(2007)
Canada DSM-IV anxiety
disorders
Community hospital
unit, mean age 41
years, 63% female
Open trial:
GCBT: 115
10 × 120 minute sessions Allied health
professionals
SCID-IV BDI-II, BAI 15% n/a
Wetherell
et al.
(2009)
Australia Age N 60 years and
DSM-IV GAD or
ADNOS
Community, mean
age: 72 years, 84%
female
RCT:
Modular CBT: 15
E-COM: 15
CBT: 12 × 60 min
E-COM: 12 × 60 minute sessions
Masters and
doctoral level
clinicians
ADIS-IV HARS, PSWQ, BDI-II, SF-36 Modular CBT:
20%
E-COM: 20%
− ? +−−
Wuthrich and
Rapee
(2013)
Australia Age N 60 and DSM-IV
primary mood or
anxiety disorder
Community, mean
age: 67 years, 65%
female
RCT
GCBT: 25
WLC: 35
12 × 120 min Clinical
psychologist and
graduate students
ADIS-IV GDS, CES-D, GAI, PSWQ, SF-12 GCBT: 12%
WLC: 3%
− ?−−−
Zou et al.
(2012)
Australia Age N 59 and DSM-IV
primary mood or
anxiety disorder
Community, mean
age: 66 years, 68%
female
Open trial: iCBT: 22 5 lessons over 8 weeks Clinical
psychologist
MINI GAD-7, PHQ-9, SDS 0% n/a
Note. Countries: USA=United States of America, UK=United Kingdom. Treatments: ACT= acceptance and commitment therapy, CBT= cognitive behaviour therapy, CG-ERP= clinician guided exposure and response prevention, DS= disorder-
speciﬁc, E-COM= enhanced community treatment, F-SET = false safety behaviour elimination therapy, GCBT= group cognitive behaviour therapy, GMBSR= group mindfulness based stress reduction, iCBT= internet-delivered cognitive behav-
ioural therapy, iCBT (CO) = internet cognitive behavioural therapy with coach guidance, iCBT (CL) = internet cognitive behavioural therapy with clinician guidance. RT = relaxation training, SC = supportive counselling, SG-ERP = self-guided
exposure and response prevention, STPP: short-term psychodynamic psychotherapy, T-CBT = telephone-delivered cognitive behaviour therapy, TAU = treatment as usual, TD = transdiagnostic WLC = waiting list control. Participants: GAD=
generalised anxiety disorder, MADD =mixed anxiety and depressive disorder, MDD = major depressive disorder, OCD = obsessive compulsive disorder, Panic/Ag = panic disorder and/or agoraphobia, PTSD = posttraumatic stress disorder,
SocPhob = social phobia or social anxiety disorder. Trial types: RCT = randomised controlled trial. Measures: ADIS-IV: Anxiety Disorders Interview Schedule for DSM-IV; ADIS-R: Anxiety Disorders Interview Schedule-Revised; AKUADS: Aga
Khan University Anxiety and Depression Scale; ASI: Anxiety Sensitivity Index, BAI: Beck Anxiety Inventory; BAT: Behavioural Activation Test; BDI-II: Beck Depression Inventory, second edition; BSI : Brief Symptom Inventory; CAQ: Cognitive Anxiety
Questionnaire; CGI: Clinical Global Improvement-Patient Rating, CID: Clinical Interview for Depression; CORE-OM: Clinical Outcome's in Routine Evaluation; DASS-21: Depression Anxiety and Stress Scales (DASS) 21-item version; DASS-42: Depres-
sion Anxiety and Stress Scales (DASS) 42-item version; EFI: Effects on Life Inventory; FI: Fear Inventory; FNE: Fear of Negative Evaluation Scale; FQ: Fear Questionnaire; FQAD: Fear Questionnaire Anxiety–Depression Subscale; FQSP: Fear Question-
naire Social Phobia Subscale; FSS: Fear Survey Schedule; GAD-7: Generalised Anxiety Disorder 7-item scale; GAS: Generalised Anxiety Scale from the Guys/Age Concerned Survey; HADS-A: Hospital Anxiety and Depression Scale— Anxiety Subscale;
HADS-D: Hospital Anxiety and Depression Scale— Depression Subscale; HAI: Health Anxiety Inventory; HARS: Hamilton Anxiety Rating Scale; HRSD: Hamilton Rating Scale for Depression; K-10: Kessler 10-item; LSAS-SR: Liebowitz Social Anxiety
Scale self-report version; MADRS-S: Montgomery–Asberg Depression Rating Scale — self rated version; MASQ: Mood and Symptoms Questionnaire; MIA: Mobility Inventory for Agoraphobia; NEO-N: NEO-Five Factor Inventory—Neuroticism Sub-
scale; OCI-R: Obsessive–Compulsive Inventory—Revised Version; PANAS: Positive and negative affect scale; PAS: Panic and Agoraphobia Scale; PCL-C Posttraumatic Stress Disorder Checklist— Civilian; PSC: Psychosomatic Symptom Checklist; PDSS-
SR: Panic Disorder Severity Scale— Self report; PRCA: Personal Report of Communication Apprehension; PRCS: Personal Report of Conﬁdence as a Speaker; PSI: Physical Symptoms inventory; PSWQ: Penn StateWorry Questionnaire; QLESQ: Quality
of Life Enjoyment and Satisfaction Scale; QOLI: Quality of Life Inventory; SAD: Social Avoidance and Distress Scale; SDS: Sheehan Disability Scale; SIAS: Social Interaction Anxiety Scale; SIAS/SPS6 composite: Social Interaction Anxiety Scale and Social
Phobia Scale 6-item composite; SIGH: Structured Interview Guide for the Hamilton Anxiety Rating Scale (A = Anxiety, D = Depression); SPSQ: Social Phobia Screening Questionnaire; SQ: Kellner's Symptom Questionnaire; SSPS: Self-Statements
During Public Speaking (positive and negative subscales); SSS: Subjective Symptoms Scale (measure of interferencewith daily functioning) STAI: State-Trait Anxiety Inventory (T= trait, S= state);WSAS:Work and Social Adjustment Scale; YBOCS:
Yale Brown Obsessive Compulsive Scale; Zung SRSD: Zung Self-Rating Scale for Depression. Qual = risk of bias coding where - = low risk of bias, + = high risk of bias, and ? = unclear risk of bias on the following indices: random sequencing,
allocation concealment, blinding of outcome assessment, incomplete outcome data, and selective reporting.
a The data from this study was analysed together with Norton and Hope (2005) who reported depression-related outcomes.
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Fig. 1. Study ﬂow chart.
102 J.M. Newby et al. / Clinical Psychology Review 40 (2015) 91–1104.5. Synthesis of results4.5.1. What are the effects of transdiagnostic psychological treatments on
primary outcomes between pre- and post-treatment (uncontrolled effect
sizes)?
The analysis of studies that reported pre- to post-treatment effects
showed a mean effect size (Hedges g) of 0.86 for anxiety (n = 50)
(95%CI: .75–.96, p b .001), 0.91 for depression (n = 41) (95%CI: .78–
1.04, p b .001), and .69 for quality of life (QOL) (n = 29) (95%CI:
.59–.78, p b .001). Hedges g values for transdiagnostic treatments, at
post-treatment on anxiety and depression are presented in Figs. 2 and
3 respectively (and see Fig. 4 for QOL outcomes). Heterogeneity was
moderate to high, and signiﬁcant amongst these studies (anxiety:
I2 = 72, depression: I2 = 78, QOL: I2 = 43). Heterogeneity remainedsigniﬁcant even after removal of studies investigating older samples,
after removal of studies with high proportion of male participants, and
after removal of potential outliers (ps b .001).
4.6. Subgroup analyses of uncontrolled pre- to post-treatment effects
4.6.1. Is there a differential effect of transdiagnostic interventions on depres-
sion versus anxiety symptoms between pre- and post-treatment?
For the ﬁrst subgroup analysis, we selected only the studies that re-
ported both depression and anxiety (n= 39) outcomes to evaluate the
magnitude of the uncontrolled (before and after treatment) effects for
depression and anxiety symptomswhen both are targeted as outcomes
and to compare these effects. Transdiagnostic interventions had large
effects on both anxiety (g= .85) and depression (g= .92), but overall
had a larger effect on depression symptoms compared to anxiety symp-
toms (Q= 3.94, df= 1, p= .047).
Fig. 2. Forest plot of within-group effect of transdiagnostic treatment on self-reported anxiety (uncontrolled pre–post-effect sizes).
103J.M. Newby et al. / Clinical Psychology Review 40 (2015) 91–1104.6.2. What is the impact of treatment delivery format on pre-to-post-
treatment outcomes?
In the next subgroup analyses (see Table 2), we compared themean
uncontrolled effect for subgroups based on treatment delivery format
(individual, group and computer/internet interventions), and found sig-
niﬁcant differences for anxiety symptoms (Q=31.75, df=2, p b .001).
While we were unable to compare between speciﬁc formats, obser-
vation of the means suggests that group-based treatments yielded
lower effects (n = 18: g = .70) than individual (n = 15: g = .97)
and computer/internet treatments (n = 17: g = .96).5 There were
also signiﬁcant group differences in the size of the uncontrolled ef-
fects for depression symptoms (Q = 12.41, df = 2, p = .002), with
observation of the means indicating that the highest effect sizes
were found in computerised/internet treatments (n = 16: g =
.96), followed by group-based face-to-face treatments (n = 12:
g = .89) and individual treatments (n = 13: g = .86). However,
there were no signiﬁcant differences between studies which used
computer, group, or individual treatment for quality of life measures
(individual, n = 10: g = .68, computer/internet, n = 15: g = .74,
group, n = 4: g = .65, Q = 3.5, df = 2, p = .17).5 For the purposes of the subgroup analyses, we coded Craske et al. (2007) as ‘group’
based treatment because themajority of treatmentwas providedwithin the group setting,
and Brenes et al., 2012 as ‘individual,’ as the telephone-based CBT was administered
individually.4.6.3. What is the impact of treatment type on pre-to-post-treatment
outcomes?
In the next subgroup analysis (see Table 2), we compared the mean
uncontrolled effect for subgroups based on treatment type (CBT versus
mindfulness/acceptance based interventions), and showed that there
was a signiﬁcant difference favouring CBT compared with mindfulness/
acceptance based interventions for reducing anxiety symptoms (Q =
7.95, df= 1, p= .005) (CBT, n= 40: g= .88, mindfulness/acceptance,
n=7: g=.61). This difference remained signiﬁcant even after removing
an outlier (Arch et al., 2013). Therewere no signiﬁcant differences across
treatment type for depression symptoms (Q= .78, df= 1, p= .38), al-
though observation of the uncontrolled effect estimate suggests that it
was slightly higher (albeit not signiﬁcant) in themindfulness/acceptance
interventions (mindfulness/acceptance, n=6: g= .92, CBT, n=31: g=
.84). Quality of life was not assessed because only one mindfulness/
acceptance study included an appropriate measure.
4.7. Effects of transdiagnostic psychological treatments on primary outcomes
between pre-treatment and follow-up (uncontrolled effect sizes)
There were 24 studies that reported follow-up data (15 reporting
3-month follow-up and 9 studies reported 6-month follow-up data).
Pre-treatment to follow-up uncontrolled effects were large on average
for anxiety (g = 0.87, n = 24, 95%CI: .73–1.01, p b .001), depression
Fig. 3. Forest plot of the within-group effect of transdiagnostic treatment on self-reported depression (uncontrolled pre–post-effect sizes).
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quality of life (g=0.75, n=16, 95%CI: .59–.91, p b .001). Heterogeneity
wasmoderate to high across all measures (anxiety: I2= 72, depression:
I2 = 88, QOL: I2 = 73).
4.8. Between-group effects of transdiagnostic psychological interventions
versus control groups
We compared the effects of transdiagnostic treatments with control
groups in 24 studies (see Figs. 5, 6, and 7 for forest plots of anxiety,
depression, and quality of life outcomes respectively). These analyses
excluded studies that compared transdiagnostic treatments with alter-
native transdiagnostic interventions, with disorder-speciﬁc interven-
tions, and comparisons between alternative versions of the same
programme. The overall effect was medium for anxiety severity (n =
24, g= .65, 95%CI: .51–.79), with moderate and signiﬁcant heterogene-
ity (I2=51), large for depression (n=22, g= .80, 95%CI: .62–.98), with
moderate heterogeneity (I2 = 66), and medium for quality of life
measures (n= 13, g= .46, 95%CI: .34–.57).
4.8.1. Subgroup analyses: does the magnitude of effect depend on the type
of control condition?
Next, we conducted a subgroup analysis to explore whether the
magnitude of between-group controlled effect differs according to the
type of control condition (WLC: n= 13, TAU: n= 4, attention control:
n = 8) and found that there was a signiﬁcant overall effect of control
condition on anxiety outcomes (Q = 19.56, df = 2, p b .001).Comparisons between transdiagnostic treatments versus TAU control
conditions had the smallest differences (g = .24, 95%CI: .05–.43,
p b .01), whereas there were large differences in comparisons between
transdiagnostic treatments and attention control conditions (g = .80,
95%CI: .52–1.08, p b .001) and WLC conditions (g = .70, 95%CI:
.56–.84, p b .001).
For depression, there was also a signiﬁcant difference in the magni-
tude of effect depending on the type of control condition (Q = 7.08,
df = 2, p = .029), with comparisons with TAU control conditions
again showing the smallest difference (g= .57, n= 4, 95%CI: .38–.76,
p b .001), followed by attention controls (g = .69, n = 8, 95%CI:
.46–.91, p b .001) and WLC having the largest difference compared to
transdiagnostic treatments (g = 1.0, n = 12, 95%CI: .69–1.30,
p b .001). The results of quality of life measures did not reach conven-
tional signiﬁcance (Q = 1.40, df = 2, p = .49) (WLC: n = 7, g = .53,
95%CI: .34–.71, p b .001, TAU: n= 2, g = .37, 95%CI: .16–.58, p b .001,
and attention control conditions: n = 4, g = .42, 95%CI: .16–.68,
p b .001), however there were only two comparisons with TAU control
conditions.
4.9. Risk of bias across studies
There was some evidence of publication bias as demonstrated by in-
spection of the funnel plot (see Appendix C), and using Duval and
Tweedie's Trim and Fill procedure. After adjusting for publication bias
using the Trim and Fill procedure, the estimate of the mean effect size
comparing transdiagnostic interventions to controls on anxiety reduced
Fig. 4. Forest plot of the within-group effect of transdiagnostic treatment on self-reported quality of life (uncontrolled pre–post-effect sizes).
105J.M. Newby et al. / Clinical Psychology Review 40 (2015) 91–110from g=.66 to g=.46 (n=9studies removed). Therewas no evidence
of publication bias for depression outcomes, nor for quality of life.4.10. Comparisons between transdiagnostic treatments versus disorder-
speciﬁc treatments
Only four studies compared transdiagnostic interventions to
disorder-speciﬁc treatment control conditions. The analysis showed
that there were no signiﬁcant differences between transdiagnostic
and disorder-speciﬁc treatments for anxiety (n = 4, g = .15,
95%CI:− .09–.38, p= .22, I2 = 0, p N .05), but there were signiﬁcant
differences for depression outcomes, with the results in favour of
the transdiagnostic treatments (n = 3, g = .58, 95%CI: .003–1.16,
p = 0.05). Notably, there was high heterogeneity (I2 = 76, p b .05)
amongst these effects.Table 2
Subgroup analyses.
Subgroup analyses Measure
Treatment format Individual Anxiety
Computer/internet
Group
Individual Depression
Computer/internet
Group
Individual QOL
Computer/internet
Group
Treatment type CBT Anxiety
Mindfulness/acceptance
CBT Depression
Mindfulness/acceptance
Note. CBT = cognitive behavioural therapy; CI = conﬁdence interval; N = number of studies;5. Discussion
In the current study, we systematically reviewed the existing litera-
ture on transdiagnostic psychological treatments for depression and anx-
iety disorders in adults.We examined their overall effect on symptoms of
depression, anxiety, and quality of life, as well as the relative efﬁcacy
of transdiagnostic treatments compared to waitlist controls (WLC),
treatment-as-usual conditions (TAU), attention control conditions and
disorder-speciﬁc treatments. We identiﬁed 47 studies (including 31
RCTs) with a total of 3705 participants evaluating transdiagnostic treat-
ments. Themajority of included studies investigatedCBTprotocols or var-
iants of CBT, and a variety of treatment delivery formats were evaluated,
with face-to-face group treatment the most commonly studied.
Analysis of the results across all studies that reported baseline and
post-treatment data showed that transdiagnostic treatments lead to
large and signiﬁcant reductions in both anxiety and depression, andN g 95%CI I2
15 .97 .73–1.21 75.7
17 .96 .85–1.07 30.3
18 .70 .53–.87 72.4
13 .86 .66–1.05 57.0
16 .96 .76–1.16 77.6
12 .89 .62–1.17 85.5
10 .68 .46–.90 67.7
15 .74 .65–.83 0
4 .65 .42–.89 27.2
40 .88 .77–1.0 71.6
7 .61 .37–.86 66.7
31 .84 .71–.95 73.1
6 .92 .44–1.39 86.3
QOL = quality of life.
Fig. 5. Forest plot of controlled between-group effect sizes for comparisons between transdiagnostic treatments and control conditions on self-reported anxiety.
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(three to sixmonths after treatment) also suggest that these positive out-
comes are maintained following treatment. However, the evidence of
high heterogeneity suggests that there were signiﬁcant differences in
treatment effects across studies. Importantly transdiagnostic treatments
seem to have a large effect on both depression and anxiety symptoms
in studies that targeted both outcomes, providing important support for
their transdiagnostic utility. There was also some preliminary evidence
that in studies that measured both outcomes, the effects were larger for
depression than anxiety. Because the majority of studies only examined
general measures of anxiety, the impact on speciﬁc mechanisms and
outcomes that characterise different fears (e.g., fears of social situations,
or fears of physical sensations) still remains unclear. Nevertheless, these
positive effects of transdiagnostic treatments are consistent with theFig. 6. Forest plot of controlled between-group effect sizes for comparisons betweenﬁndings of previousmeta-analyses (Norton & Philipp, 2008) and a narra-
tive review (McEvoy et al., 2009). Notably, our effect estimates for anxiety
were lower than a previous meta-analysis of TD-CBT (Norton & Philipp,
2008 who found d= 1.29). This may be because we evaluated a wider
range of treatment protocols, or because of methodological differences
between studies. For example, we only included studies which employed
more rigorous inclusion criteria (e.g., used structured diagnostic in-
terviews).We also usedHedges g rather than Cohen's d, which provides a
more conservative estimate of effect sizes by adjusting for small sample
sizes.
The majority of trials compared transdiagnostic treatments to WLC,
but transdiagnostic treatments were also compared to a range of
attention control conditions that included psychoeducation, online dis-
cussion forums, and supportive counselling. There was only one directtransdiagnostic treatments and control conditions on self-reported depression.
Fig. 7. Forest plot of controlled between-group effect sizes for comparisons between transdiagnostic treatments and control conditions on self-reported quality of life.
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compare the efﬁcacy of transdiagnostic psychological treatments to
pharmacological interventions for depression and anxiety. Analysis of
the pooled results from the RCTs demonstrated that transdiagnostic
treatments outperformed controls on all three outcomemeasures. Sim-
ilar to Reinholt and Krogh (2014), we found moderate differences be-
tween transdiagnostic treatments and control conditions in anxiety
severity at post-treatment. We also demonstrated large overall differ-
ences between transdiagnostic treatments and control condition in de-
pression severity, and moderate differences in quality of life at post-
treatment. This is the ﬁrst meta-analysis to demonstrate the positive
impact of transdiagnostic treatments on improving quality of life. Com-
pared to the effects found in a recent meta-analysis of CBT for anxiety
disorders on quality of life outcomes, our uncontrolled effects were
slightly higher (g = .69, versus g = .54 in Hofmann, Wu, & Boettcher,
2014), but the controlled effects were slightly lower (g = .46 versus
g = .56 averaged across group, individual and internet treatments in
Hofmann et al., 2014). Heterogeneity was also moderate to high for all
outcomemeasures, suggesting therewas signiﬁcant variability amongst
these effects. We also found some evidence of publication bias for anx-
iety outcomes, which suggests these effect estimatesmay be inﬂated. In
addition, the quality assessments revealed that 24 out of 31 RCTs were
at high risk of ﬁnding biased estimates of effects, based on commonly
used risk of bias indices (Higgins & Green, 2011).
Our preliminary results suggest that the nature of the control con-
dition inﬂuenced the size of treatment effects in this study, which may
in part explain some of the heterogeneity we observed. We found
large differences between transdiagnostic treatments compared to
both WLC and attention control conditions (e.g., psychoeducation, on-
line discussion forums, relaxation training). In contrast, we found only
small overall differences in studies that compared transdiagnostic treat-
ments to TAU or ‘usual care’ control conditions in anxiety outcomes,
which supports the ﬁndings of Reinholt and Krogh (2014). These results
demonstrate that transdiagnostic treatments have beneﬁts over and
above the natural recovery processes that often occur across time dur-
ing the course of depression and anxiety problems (e.g., spontaneous
recovery), as well as the non-speciﬁc or ‘common’ therapeutic factors
associatedwith treatment thatmay account for symptom improvement
(e.g., therapeutic alliance, regular assessment and monitoring).
It is unclear why there was a smaller difference between transdiag-
nostic treatments compared to usual care, whereas transdiagnostic
treatments outperformed other control conditions to a larger degree.
It is possible that the use of TAU control conditions was confounded
with the type of treatment, the duration of the treatment period being
evaluated, the quality of the study, or the country where the study
was conducted. Three of the four studies were coded as having lowrisk of bias on all measures. Two of the four studies that used TAU con-
trol conditions evaluated alternative forms of psychotherapy (other
than CBT) such as problem-solving therapy and short-term psychody-
namic psychotherapy in China and Italy, respectively. The remaining
two studies compared computerised CBT to TAU in the United
Kingdom. If participantswith depression and anxiety disorders received
relatively effective psychological and/or pharmacological treatments as
part of their usual care in these studies, this may account for the smaller
difference we observed. For example, one of these studies (Bressi,
Porcellana, Marinaccio, Nocito, & Magri, 2010) compared 40 sessions
of short-term psychodynamic psychotherapy for depression and anxi-
ety delivered by Psychiatrists over a 12-month period to 12 months of
TAU, which consisted of drug treatment combined with “interviews”
with a Psychiatrist, which could be scheduled up to four times per
month. In this study, it is likely that TAU provided a strong comparison
condition. Because therewas no independent coding of what the “inter-
views” entailed, it is even possible that the Psychiatrists in the TAU con-
dition delivered similar psychotherapy to the treatment condition.
These ﬁndings highlight the need for closer examination of what TAU
entails, and highlight the need for future meta-analytic reviews to dis-
tinguish studies that use TAU versus WL/no-treatment controls when
estimating the value of new treatments (Watts, Turnell, Kladnitski,
Newby & Andrews, 2015).
Another aim of this study was to examine the efﬁcacy of transdiag-
nostic treatments relative to disorder-speciﬁc treatments, in an attempt
to clarify the mixed ﬁndings in the literature. When compared to the
effect sizes found in recent meta-analyses of disorder-speciﬁc interven-
tions, the overall effect size difference compared to control conditions is
slightly lower than the0.84 large effect size for reduction in anxiety symp-
toms across psychological treatments for GAD (Cuijpers et al., 2014), but
higher than average effect sizes for psychological interventions for de-
pression (0.53) (Cuijpers, Andersson, Donker, & Van Straten, 2011). We
found only four studies that directly compared transdiagnostic versus
disorder-speciﬁc treatments for anxiety and depression, which makes it
difﬁcult to draw deﬁnitive conclusions about their relative impact. How-
ever, our preliminary results suggested that on average, transdiagnostic
treatments are at least as efﬁcacious as disorder-speciﬁc treatments in
reducing anxiety symptoms, and there may be small effects in favour of
the transdiagnostic treatments on depression symptoms. Although
these results are very preliminary and need to be replicated with a larger
number of studies, it suggests that there may be advantages of using a
transdiagnostic approach for treating depression symptoms when de-
pression is experienced in the context of comorbid anxiety symptoms.
While comparing their differential effects on symptoms is important, fu-
ture studies also need to compare transdiagnostic and disorder-speciﬁc
treatments on measures of acceptability to patients and clinicians, their
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effectiveness.
We included studies of a range of interventions that adopted the
transdiagnostic approach to treatment. Although some studies speciﬁ-
cally labelled their intervention as a ‘transdiagnostic treatment,’ many
did not use this terminology. The high level of heterogeneity suggests
that there were signiﬁcant differences in treatment outcomes across
these studies, which may be due to critical differences between proto-
cols. Our preliminary ﬁndings indicated potential sources of the hetero-
geneity: both treatment type (CBT versusmindfulness/acceptance) and
delivery format (face-to-face individual, face-to-face group, or clinician-
guided computerised/internet delivery) inﬂuenced outcomes. For exam-
ple, on average we found that group-based face-to-face transdiagnostic
treatments had the smallest (but still moderate to large) effects on anxi-
ety and depression symptoms. Internet-delivered and computerised
treatments had the largest effect sizes for depression, andhad large effects
on anxiety measures, which were similar to the effects found on anxiety
measures in individual treatments.
Computerised and internet therapies typically comprise online/
computerised modules or lessons that are delivered over a deﬁned
treatment period (e.g., 12 weeks). These text-based lessons/modules
teach the patient about depression/anxiety and how to manage their
symptomsusingpractical skills (e.g., graded exposure and thought chal-
lenging in CBT). Lessons are typically supplemented with homework
exercises to consolidate new learning and encourage skills practice in
the patient's daily life, and clinician guidance is often provided via
phone or email. Because of their standardised nature, computerised
treatments have high treatment ﬁdelity. Since our search was conduct-
ed, two additional RCTs have found large and positive effects of
transdiagnostic internet CBT for mixed anxiety disorders, providing
more evidence in support for their efﬁcacy (Dear, Zou, Ali, et al., 2014;
Nordgren et al., 2014). Future research is critically needed to identify
why different treatment effects are observed across delivery formats,
and whether it is actually the format of delivery or other aspects of
the treatment protocol or participant samples that inﬂuence outcomes.
Our results also suggested that, on average, CBT signiﬁcantly out-
performedmindfulness/acceptance-based treatments in reducing anxi-
ety symptoms, but not depression. These results need to be interpreted
with caution given that therewere relatively few studies of ‘third-wave’
therapies, and a diverse range of therapies were included in this catego-
ry. It is possible that CBTwasmore powerful in reducing anxiety overall
because exposure-based techniques are included as a core component
in these protocols. Given that themost commonly usedmeasure of anx-
iety was the BAI, which has been argued to capture symptoms of auto-
nomic arousal rather than other features of anxiety (e.g., worry), it is
also possible that CBT is simply more powerful in reducing anxious
arousal. This hypothesis is in line with the non-signiﬁcant but small ef-
fects in favour of CBT over MBSR on measures of arousal found by Arch
et al. (2013). Nevertheless, our study highlights the need for more high
quality, adequately powered research studies to compare the differ-
ential effects of the CBT versus mindfulness- and acceptance-based
transdiagnostic treatments on a range of outcome measures (anxiety
and depression), and to identify active components that contribute to
positive outcomes. Further studies are also needed to explore whether
combining conventional or adapted transdiagnostic CBT protocols with
mindfulness and/or acceptance-based treatment approaches has any
added beneﬁt for the treatment of emotional disorders.
While our results go part way to explaining some of the heterogene-
ity amongst treatment effects, more research is needed to understand
additional sources of heterogeneity. Our review included a diverse set
of protocols that included integral (where all patients receive the
same ﬁxed protocol), modular and case-formulation driven treatments,
as well as tailored interventions that target a patient's primary disorder
and comorbid symptoms. The protocols also varied in number and type
of anxiety and depressive disorders that were targeted, and the samples
varied in terms of severity and comorbidity. It remains unclearwhich type of transdiagnostic treatment approach is more effective,
whether therapist experience inﬂuences outcomes, and whether the
transdiagnostic treatments are more suitable to speciﬁc symptom pro-
ﬁles or diagnostic combinations. In future, it would be helpful to inde-
pendently review all of the transdiagnostic treatment protocols that
have been evaluated to-date, and compare the treatment components/
elements in the protocols that yield the highest effects to those that
yield the lowest effects. This may assist in identifying the treatment
components that promote positive outcomes for patients, and the
most efﬁcacious approach to use when implementing a transdiagnostic
protocol.5.1. Limitations
The results of this review need to be interpreted in the context of
some limitations. First, due to practical reasons, we only included stud-
ies that were published in English; grey literature and unpublished
studies were not included in the meta-analysis. Second, our search
was restricted to a limited set of databases (PSYCInfo and PubMed). Al-
thoughwe attempted to address this by examining the reference lists of
previousmeta-analyses and relevant papers, wemay have unintention-
ally omitted articles that met our inclusion criteria because of our re-
stricted search. Third, because we restricted our inclusion criteria to
manualised interventions, this is likely to have introduced some bias to-
wards the inclusion of studies of CBT, and exclusion of psychological
treatments from other treatment orientations such as psychodynamic
psychotherapies (e.g., see Knekt et al., 2008). Interestingly, evaluation
of a uniﬁed protocol for the transdiagnostic psychodynamic treatment
of anxiety disorders is now underway which will provide a better un-
derstanding of the efﬁcacy of psychodynamic treatments that adopt a
transdiagnostic treatment approach (Leichsenring & Salzer, 2014).
Fourth, we only examined the impact of transdiagnostic treatments
using self-report measures because clinician-rated instruments were not
consistently used across studies, which may have resulted in inﬂated es-
timates of effect sizes. Future studies need to examine the impact of
these treatments on both clinician-rated and self-reported instruments.
Fifth,we did not use ameasure of bias risk in the non-randomised studies,
although the major methodological limitation of those studies is the ab-
sence of a control condition and no randomised estimate of effects. Final-
ly, we used a range of subgroup analyses to explore the possible reasons
for the high heterogeneity found in the treatment effects. Because the re-
sults from our subgroup analyses are purely observational (Borenstein &
Higgins, 2013), we cannot conclude that treatment type and format
caused the differences in outcomes we observed in outcomes. It is also
possible that the subgroups differed in other important ways that inﬂu-
enced outcomes (e.g., therapist experience, choice of assessment mea-
sure, or quality of study design).6. Conclusions
Despite these limitations, the strength of our study is that it is the
ﬁrst to review systematically the comprehensive set of transdiagnostic
treatments, across treatment types (e.g., CBT, mindfulness/acceptance
and other treatment approaches) and delivery formats (e.g., face-to-
face individual and group, as well as computerised treatments). Our re-
sults provide evidence in support of the efﬁcacy of transdiagnostic
treatments in reducing depression and anxiety, and improving quality
of life. The quality of RCTs was low overall, and heterogeneity was
high. Further high quality RCTs are now needed to explore the sources
of this heterogeneity to identify the most effective treatment compo-
nents and designs, and to understand how transdiagnostic treatments
work.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cpr.2015.06.002.
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